SCHEMBL3323366

SCHEMBL3323366

CCCCOC(=O)C1=C(C)NC2=C(C(=O)CCC2)C1c1ccc(Cl)cc1

nearest known ligand 0.70

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 12/20 0.70
KDM4E B2RXH2 15/20 0.66
HSD17B10 Q99714 7/20 0.66
CASP1 P29466 5/20 0.65
CASP7 P55210 5/20 0.65
MAPK1 P28482 1/20 0.65
SMN1; SMN2 Q16637 1/20 0.65
TP53 P04637 1/20 0.61
POLB P06746 1/20 0.61
HPGD P15428 5/20 0.60
ALOX15 P16050 1/20 0.59
GAA P10253 3/20 0.58
HTT P42858 1/20 0.58
L3MBTL1 Q9Y468 1/20 0.57
BAP1 Q92560 1/20 0.56
TSHR P16473 1/20 0.55
MEN1 O00255 1/20 0.54
KMT2A Q03164 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3320549 0.91 KDM4E (0.77) ALDH1A1KDM4EHSD17B10CASP1CASP7
SCHEMBL3325251 0.90 ALDH1A1 (0.70) ALDH1A1KDM4EHSD17B10CASP1CASP7
SCHEMBL3325552 0.89 KDM4E (0.64) ALDH1A1KDM4EHSD17B10CASP1CASP7
SCHEMBL13333270 0.88 ALDH1A1 (0.70) ALDH1A1KDM4EHSD17B10CASP1CASP7
SCHEMBL3327667 0.86 KDM4E (0.61) ALDH1A1KDM4EHSD17B10CASP1CASP7
SCHEMBL3325228 0.86 ALDH1A1 (0.81) ALDH1A1KDM4EHSD17B10CASP1CASP7
SCHEMBL12784576 0.86 ALDH1A1 (0.64) ALDH1A1KDM4EHSD17B10CASP1CASP7
SCHEMBL3326956 0.85 KDM4E (0.70) ALDH1A1KDM4EHSD17B10CASP1CASP7
SCHEMBL3325585 0.85 KDM4E (0.53) ALDH1A1KDM4EHSD17B10CASP1CASP7
SCHEMBL3323236 0.85 ALDH1A1 (0.80) ALDH1A1KDM4EHSD17B10CASP1CASP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100119599-A1 POLYHYDROQUINOLINE COMPOUNDS AND DIHYDROPYRIDINE COMPOUNDS FOR INHIBITING BETA-AMYLOID PRODUCTION ARCHER PHARMACEUTICALS, INC. (US) 2010-05-13 US disclosed
US-20100119599-A1 POLYHYDROQUINOLINE COMPOUNDS AND DIHYDROPYRIDINE COMPOUNDS FOR INHIBITING BETA-AMYLOID PRODUCTION ARCHER PHARMACEUTICALS, INC. (US) 2010-05-13 US disclosed
US-20100119599-A1 POLYHYDROQUINOLINE COMPOUNDS AND DIHYDROPYRIDINE COMPOUNDS FOR INHIBITING BETA-AMYLOID PRODUCTION ARCHER PHARMACEUTICALS, INC. (US) 2010-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100119599-A1 POLYHYDROQUINOLINE COMPOUNDS AND DIHYDROPYRIDINE COMPOUNDS FOR INHIBITING BETA-AMYLOID PRODUCTION APP, MAPT, PSEN1 ALDH1A1 2615/4885KDM4E 4115/4885HSD17B10 1530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.